First ALZ-NET Data Readout Marks Milestone in Building Real-World Evidence for Alzheimer’s Treatment New clinical & imaging data reported at CTAD shows anti-amyloid drugs have similar safety & efficacy in real-world settings to tightly controlled clinical trials.

New real-world data from ALZ-NET shared for the first time at #CTAD25 shows outcomes on FDA-approved anti-amyloid therapies are consistent with clinical trials, with stable cognition/function and expected ARIA rates. Learn more: www.alz.org/news/2025/al...

Live at #CTAD25: the ALZpath #pTau217 antibody is accelerating biomarker, proteomic & longitudinal research across leading institutions.

🔗See the full list of posters & presentations: alzpath.bio/wp-content/u...

Dive into the latest in #Alzheimers & #Dementia research from biomarkers & digital outcomes to new therapies and AI in trials.

Discover late-breaking data, methods and new #Alzheimer’s trial results in #symposia, oral sessions & posters.

#CTAD25 brings the latest breakthroughs.